February 4, 2023

Beyond Biotech podcast 32: Cancer Research Horizons, Enterome, OncoHost, TrakCel, Turbine

Original source here.

Our guests are Ofer Sharon, CEO of OncoHost; Matthew Lakelin, co-founder, TrakCel; Pierre Belichard, CEO of Enterome; and Tony Hickson, chief business officer for Cancer Research UK and Cancer Research Horizons and Daniel Veres, chief science officer and co-founder, Turbine.

World Cancer Day

February 4 is World Cancer Day. This year, the theme is Close the Gap. For the podcast this week, we feature four interviews related to cancer.

OncoHost launches PROphet NSCLC test in the US

OncoHost, a precision diagnostics company centered on predictive biomarker development for improved patient care, has launched its PROphet non-small cell lung cancer (NSCLC) test in the U.S.

PROphet NSCLC guides first-line treatment decisions for advanced unresectable non-small lung cancer patients. It provides clinicians with actionable clinical insights into optimal first-line therapeutic choices and a better understanding of their patients’ personalized cancer dynamics. Requiring just one pre-treatment blood test, PROphet scans approximately 7,000 proteins in a patient’s blood plasma and delivers a report that predicts their clinical benefit from anti-PD-1/PD-L1 immunotherapy-based treatment plans.

“After years of research, development, and determination, we are proud to be launching our PROphet NSCLC test in the United States,” said Ofer Sharon, CEO of OncoHost.

“While driver mutation detection is essential in determining effective treatment, approximately 85% of all patients diagnosed with NSCLC do not have any detectable driver mutations. In these cases, the PROphet NSCLC Test, when combined with PD-L1 results, will serve an invaluable purpose in predicting the best treatment plan for each individual patient. We hope to create a shift in the industry and improve the lives of those fighting this disease.”

The PROphet algorithm is trained on OncoHost’s large-scale clinical trial, PROPHETIC. To date, the trial has over 1,500 patients recruited across 40 sites worldwide, making it one of the largest prospective cohorts in the precision oncology field. The PROphet NSCLC test is supported by a blinded validation demonstrating that it accurately predicts a patient’s clinical benefit and associated overall survival differences with single-agent versus combination treatment plans.